HanchorBio Expands Clinical Data Disclosures with Q1 2026 Oncology Congress Presentations
Event summary
- HanchorBio scheduled 11 scientific presentations across 6 major oncology congresses in Q1 2026, including 4 oral presentations.
- Clinical data from HCB101 and HCB301 programs will be featured, highlighting their CD47-SIRPα innate immune backbone technology.
- HCB101 demonstrated high objective response rates in second-line gastric cancer at ASCO GI in January 2026.
- HCB301 is a tri-specific immunotherapy targeting CD47/SIRPα, PD-1/PD-L1, and TGF-b pathways.
The big picture
HanchorBio's aggressive Q1 2026 presentation schedule underscores its push to establish clinical leadership in next-generation immuno-oncology therapies. The focus on multi-specific approaches comes as the industry shifts toward combination therapies to overcome resistance mechanisms in cancer treatment. Success in these disclosures could position HanchorBio as a key player in the evolving innate immune checkpoint space.
What we're watching
- Clinical Validation
- Whether HCB101 and HCB301 can demonstrate sustained efficacy across multiple tumor types and combination settings.
- Regulatory Pathway
- The pace at which HanchorBio advances these assets through Phase 2 and potential pivotal studies.
- Competitive Positioning
- How HanchorBio differentiates its CD47-SIRPα approach from competitors in the crowded immuno-oncology space.
Related topics